Skip to main content
FDA approves Herceptin biosimilar, but launch date is uncertain

The FDA approved Ogivri, a biosimilar of Roche's Herceptin made by Mylan and Biocon, to treat breast and stomach cancers. A licensing agreement makes the launch date uncertain, according to one analyst; another says the biosimilar will not hit the market until 2019.

Full Story: